Hopefully no one makes the mistake of thinking these drugs are an appropriate first line management step in patients with life-threatening hyperkalemia.

Posted 30 Nov, 2014 at 19:07

Related Papers

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. Matthew R Weir, George L Bakris, David A Bushinsky, Martha R Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ-Schmidt, Lance Berman, Bertram Pitt New England Journal of Medicine 2015 January 15, 372 (3): 211-21

Sodium zirconium cyclosilicate in hyperkalemia. David K Packham, Henrik S Rasmussen, Philip T Lavin, Mohamed A El-Shahawy, Simon D Roger, Geoffrey Block, Wajeh Qunibi, Pablo Pergola, Bhupinder Singh New England Journal of Medicine 2015 January 15, 372 (3): 222-31

Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Gil Chernin, Amir Gal-Oz, Eyal Ben-Assa, Idit F Schwartz, Talia Weinstein, Doron Schwartz, Donald S Silverberg Clinical Cardiology 2012, 35 (1): 32-6

Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Tolga Yildirim, Mustafa Arici, Serhan Piskinpasa, Aysun Aybal-Kutlugun, Rahmi Yilmaz, Bulent Altun, Yunus Erdem, Cetin Turgan Renal Failure 2012, 34 (9): 1095-9

PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Jerry M Buysse, I-Zu Huang, Bertram Pitt Future Cardiology 2012, 8 (1): 17-28

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Paweena Susantitaphong, Kamal Sewaralthahab, Ethan M Balk, Somchai Eiam-ong, Nicolaos E Madias, Bertrand L Jaber American Journal of Hypertension 2013, 26 (3): 424-41

Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system. Alan Segal New England Journal of Medicine 2004 December 2, 351 (23): 2450-1; author reply 2450-1

Zirconium cyclosilicate for treatment of hyperkalemia. Bradley S Dixon JAMA: the Journal of the American Medical Association 2014 December 3, 312 (21): 2217-8

[Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances]. Hideki Kato, Kana Kobayashi, Shunya Uchida Nihon Rinsho. Japanese Journal of Clinical Medicine 2012, 70 (9): 1536-41

Nutritional delivery in infants with CKD: techniques to avoid hyperkalemia. Timothy E Bunchman Journal of Renal Nutrition 2013, 23 (5): 387-8

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

A new era for the treatment of hyperkalemia?

Discussion

Responses

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips